Study Examines Safety of Immune Checkpoint Inhibitor Therapy in Patients With HIV

Source: Cancer Network, March 2019

No new safety or efficacy concerns were found for advanced-stage cancer patients with HIV infection who received immune checkpoint inhibitor therapy, a systematic review published in JAMA Oncologyreported. However, since the conclusions rely largely on case reports, prospective studies are needed before the safety of immune checkpoint inhibitors in cancer patients with HIV can be fully known.

“Having this type of analysis focused on cancer patients that are HIV-positive would help in adjusting the strict regulations about accepting HIV-positive individuals on clinical trials,” said Tatiana Garcia-Bates, PhD, research assistant professor of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, during an interview with Cancer Network. Historically, patients with HIV have been excluded from cancer clinical trials.

To investigate the safety and efficacy of immune checkpoint inhibitors in cancer patients with HIV, the study researchers performed a literature review and identified 13 articles (11 case reports and 2 retrospective case series) for analysis. They also reviewed the annual meeting proceedings from major oncology society conferences and found 4 meeting abstracts for analysis.

read the original full article